PD-L1 expression in neuroendocrine tumors of the lung
| Autor: | Shintaro Kanda, Yutaka Fujiwara, Keisuke Asakura, Kenjiro Tsuruoka, Yuichiro Ohe, Hiroyuki Sakurai, Hiroshi Nokihara, Kazuo Nakagawa, Shun Ichi Watanabe, Noboru Yamamoto, Yasushi Goto, Hidehito Horinouchi, Koji Tsuta |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine Cancer Research Pathology medicine.medical_specialty Lung Neoplasms Carcinoid tumors Gene Expression Neuroendocrine tumors B7-H1 Antigen Young Adult 03 medical and health sciences 0302 clinical medicine Risk Factors Biomarkers Tumor medicine Humans Aged Neoplasm Staging Aged 80 and over Tissue microarray Lung biology business.industry Cancer Histology Middle Aged Prognosis medicine.disease Immunohistochemistry Neuroendocrine Tumors 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis biology.protein Female Antibody business |
| Zdroj: | Lung Cancer. 108:115-120 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2017.03.006 |
| Popis: | Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as follows: median age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV): 79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC): 46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as follows: TC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect